Amphastar Pharmaceuticals Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals or view top-rated stocks.

3 brokers have issued 1-year price objectives for Amphastar Pharmaceuticals' stock. Their AMPH stock forecasts range from $32.00 to $43.00. On average, they predict Amphastar Pharmaceuticals' stock price to reach $36.67 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Amphastar Pharmaceuticals' stock was trading at $23.29 at the beginning of the year. Since then, AMPH shares have increased by 36.5% and is now trading at $31.78.
View the best growth stocks for 2022 here.

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings data on Monday, May, 9th. The company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The business earned $120.37 million during the quarter, compared to the consensus estimate of $110.60 million. Amphastar Pharmaceuticals had a net margin of 17.87% and a trailing twelve-month return on equity of 17.35%. During the same period in the prior year, the company earned $0.27 EPS.
View Amphastar Pharmaceuticals' earnings history.

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amphastar Pharmaceuticals include Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Evotec (EVTCY), Cytokinetics (CYTK), Mirati Therapeutics (MRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG) and Arrowhead Pharmaceuticals (ARWR).
View all of AMPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.55%), Federated Hermes Inc. (7.14%), Vanguard Group Inc. (5.09%), Dimensional Fund Advisors LP (3.68%), State Street Corp (2.71%) and Nantahala Capital Management LLC (0.00%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Assenagon Asset Management S.A., Eagle Asset Management Inc., BlackRock Inc., SG Americas Securities LLC, Arrowstreet Capital Limited Partnership, and Nisa Investment Advisors LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last two years include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals or view top insider-selling stocks.

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Hillsdale Investment Management Inc., Penserra Capital Management LLC, Friess Associates LLC, EAM Investors LLC, Calamos Advisors LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Amphastar Pharmaceuticals or or view top insider-buying stocks.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMPH stock can currently be purchased for approximately $31.78.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.55 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.61 on an earnings per share basis.

Amphastar Pharmaceuticals employs 1,761 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for Amphastar Pharmaceuticals is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296.